Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.76 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | PLD2 | O14939 | 1/20 | 0.71 |
| ▸ | KDM1A | O60341 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | C5 | P01031 | 1/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5166121 | 0.99 | ESR1 (0.76) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL24173269 | 0.96 | ESR1 (0.80) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL11183158 | 0.94 | ESR1 (0.70) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL11192404 | 0.94 | ESR1 (0.70) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL8211353 | 0.94 | ESR1 (0.70) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL11192438 | 0.94 | ESR1 (0.67) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL9202207 | 0.93 | ESR1 (0.76) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9204830 | 0.92 | ESR1 (0.77) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL11193395 | 0.92 | ESR1 (0.72) | ESR1ESR2ENPP3MEN1ALDH1A1 | |
| SCHEMBL11196715 | 0.92 | ESR1 (0.67) | ESR1ESR2ENPP3MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1772150-A1 | Benzothiophene formulations of a specific dosage | Eli Lilly & Company (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060106010-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-RE39049-E1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-RE38968-E1 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride | ELI LILLY AND COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-6906086-B2 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1438957-A1 | Benzothiophene formulations of a specific dosage | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030212058-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-0781555-A1 | Benzothiophene formulations of a specific dosage | ELI LILLY AND COMPANY (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0584952-B1 | Improvements in or relating to benzothiophenes | LILLY CO ELI (US) | 1997-05-02 | — | — | EP | disclosed |
| US-5534527-A | TREATMENT OF OSTEOPOROSIS | ELI LILLY AND COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5464845-A | Benzo(b)thienyl derivatives | ELI LILLY AND COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5457117-A | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-5393763-A | Administering benzothiophenes such as raloxifene hydrochloride | ELI LILLY AND COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0584952-A1 | Improvements in or relating to benzothiophenes | ELI LILLY AND COMPANY (US) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106010-A1 | Methods for inhibiting bone loss | SHBG, SOST, ESRRB | ESR1 15/4885ESR2 5/4885ENPP3 307/4885 |
| US-20030212058-A1 | Methods for inhibiting bone loss | SHBG, SOST, ESRRB | ESR1 15/4885ESR2 5/4885ENPP3 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.